Phospholipase C treatment of certain human target cells reduces their susceptibility to NK lysis without affecting binding or sensitivity to lytic granules
Phosphatidylinositol-specific phospholipase C (PI-PLC) is an enzyme that has the capacity to release glycosyl-phosphatidyl inositol (G-PI)-anchored proteins from the cell surface. Pretreatment of the human T-cell leukemia cell line Molt-4 with PI-PLC resulted in a decrease in the susceptibility to l...
Gespeichert in:
| Veröffentlicht in: | Cellular immunology 1991-03, Vol.133 (1), p.127-137 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 137 |
|---|---|
| container_issue | 1 |
| container_start_page | 127 |
| container_title | Cellular immunology |
| container_volume | 133 |
| creator | Une, Clas Grönberg, Alvar Axberg, Inger Jondal, Mikael Örn, Anders |
| description | Phosphatidylinositol-specific phospholipase C (PI-PLC) is an enzyme that has the capacity to release glycosyl-phosphatidyl inositol (G-PI)-anchored proteins from the cell surface. Pretreatment of the human T-cell leukemia cell line Molt-4 with PI-PLC resulted in a decrease in the susceptibility to lysis by natural killer (NK) cells. Treatment of the erythroleukemia cell line K562 with PI-PLC had no effect on its NK susceptibility. PI-PLC-treated and untreated Molt-4 bound equally well to lymphocytes in target-binding studies with effector cell preparations enriched for NK cells. Susceptibility to cytolytic granules isolated from rat LGL tumor cells remained the same after treatment of Molt-4 or K562 with PI-PLC. Combined treatment of Molt-4 with PI-PLC and rlFN-α or rlFN-γ resulted in additive reductions of the NK susceptibility, suggesting that PI-PLC and interferons act on different mechanisms to protect cells from NK lysis. When expression of a number of antigens on Molt-4 and K562 was analyzed in flow cytometry, only the expression of CD58 was reduced after PI-PLC treatment. The susceptibility of Con A blasts to MLR derived cytotoxic T-cells was not altered by treatment with phospholipase. These data suggest that PI-PLC treatment reduces the capacity of some target cells to activate NK cells upon contact. The mechanism behind this phenomenon is presently unclear. |
| doi_str_mv | 10.1016/0008-8749(91)90185-E |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80433950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000887499190185E</els_id><sourcerecordid>80433950</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-7c6003128df69d8b4d19406cc14f13bbd041fa6d69f6fffaa7d56439282302533</originalsourceid><addsrcrecordid>eNqFkc-O1DAMhysEWmYX3gCkHBCCQ8Fp2rS5IKHRLCBWwAHOUZo406D-GeJ00TwLL0vLjJYbnCzF38-K_WXZEw6vOHD5GgCavKlL9ULxlwp4U-W7e9mGg4K84FLczzZ3yMPskug7AOelgovsgtcgVFFtsl9fuokO3dSHgyFkW5YimjTgmNjkmcWYTBhZNw9mZMnEPablse-JRXSzRWKpwxAZzWTxkEIb-pCOLE3s00fWHykQ-xlSN82JGe_RpjDuWRtGt9ZpyeFIIYXbc6g_pmDZPppx7pEeZQ-86Qkfn-tV9u1693X7Pr_5_O7D9u1NbkUjUl5bCSB40TgvlWva0nFVgrSWl56LtnVQcm-kk8pL770xtatkuazfFAKKSoir7Plp7iFOP2akpIdA65ZmxGkm3UAphKrgvyCvFBdKyQUsT6CNE1FErw8xDCYeNQe9ytOrGb2a0YrrP_L0bok9Pc-f2wHd39DJ1tJ_du4bsqb3y51soDusklCUVb1gb04YLke7DRg12YCjRRfiokC7Kfz7H78B04G4-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15913996</pqid></control><display><type>article</type><title>Phospholipase C treatment of certain human target cells reduces their susceptibility to NK lysis without affecting binding or sensitivity to lytic granules</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Une, Clas ; Grönberg, Alvar ; Axberg, Inger ; Jondal, Mikael ; Örn, Anders</creator><creatorcontrib>Une, Clas ; Grönberg, Alvar ; Axberg, Inger ; Jondal, Mikael ; Örn, Anders</creatorcontrib><description>Phosphatidylinositol-specific phospholipase C (PI-PLC) is an enzyme that has the capacity to release glycosyl-phosphatidyl inositol (G-PI)-anchored proteins from the cell surface. Pretreatment of the human T-cell leukemia cell line Molt-4 with PI-PLC resulted in a decrease in the susceptibility to lysis by natural killer (NK) cells. Treatment of the erythroleukemia cell line K562 with PI-PLC had no effect on its NK susceptibility. PI-PLC-treated and untreated Molt-4 bound equally well to lymphocytes in target-binding studies with effector cell preparations enriched for NK cells. Susceptibility to cytolytic granules isolated from rat LGL tumor cells remained the same after treatment of Molt-4 or K562 with PI-PLC. Combined treatment of Molt-4 with PI-PLC and rlFN-α or rlFN-γ resulted in additive reductions of the NK susceptibility, suggesting that PI-PLC and interferons act on different mechanisms to protect cells from NK lysis. When expression of a number of antigens on Molt-4 and K562 was analyzed in flow cytometry, only the expression of CD58 was reduced after PI-PLC treatment. The susceptibility of Con A blasts to MLR derived cytotoxic T-cells was not altered by treatment with phospholipase. These data suggest that PI-PLC treatment reduces the capacity of some target cells to activate NK cells upon contact. The mechanism behind this phenomenon is presently unclear.</description><identifier>ISSN: 0008-8749</identifier><identifier>EISSN: 1090-2163</identifier><identifier>DOI: 10.1016/0008-8749(91)90185-E</identifier><identifier>PMID: 1703925</identifier><identifier>CODEN: CLIMB8</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Antigens, CD - analysis ; Antigens, Differentiation - analysis ; Biological and medical sciences ; CD58 Antigens ; Cell Line ; Cytoplasmic Granules - enzymology ; Cytotoxic reactions (adcc reaction, cell-mediated lympholysis, complement-dependent cytotoxicity and others) ; Cytotoxicity, Immunologic - drug effects ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunity, Innate - drug effects ; Immunobiology ; Immunological reactions in vitro ; In Vitro Techniques ; Interferon Type I - pharmacology ; Interferon-gamma - pharmacology ; Killer Cells, Natural - immunology ; Lymphocyte Activation ; Signal Transduction - drug effects ; T-Lymphocytes - immunology ; Type C Phospholipases - pharmacology</subject><ispartof>Cellular immunology, 1991-03, Vol.133 (1), p.127-137</ispartof><rights>1991</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-7c6003128df69d8b4d19406cc14f13bbd041fa6d69f6fffaa7d56439282302533</citedby><cites>FETCH-LOGICAL-c383t-7c6003128df69d8b4d19406cc14f13bbd041fa6d69f6fffaa7d56439282302533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/000887499190185E$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5602457$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1703925$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Une, Clas</creatorcontrib><creatorcontrib>Grönberg, Alvar</creatorcontrib><creatorcontrib>Axberg, Inger</creatorcontrib><creatorcontrib>Jondal, Mikael</creatorcontrib><creatorcontrib>Örn, Anders</creatorcontrib><title>Phospholipase C treatment of certain human target cells reduces their susceptibility to NK lysis without affecting binding or sensitivity to lytic granules</title><title>Cellular immunology</title><addtitle>Cell Immunol</addtitle><description>Phosphatidylinositol-specific phospholipase C (PI-PLC) is an enzyme that has the capacity to release glycosyl-phosphatidyl inositol (G-PI)-anchored proteins from the cell surface. Pretreatment of the human T-cell leukemia cell line Molt-4 with PI-PLC resulted in a decrease in the susceptibility to lysis by natural killer (NK) cells. Treatment of the erythroleukemia cell line K562 with PI-PLC had no effect on its NK susceptibility. PI-PLC-treated and untreated Molt-4 bound equally well to lymphocytes in target-binding studies with effector cell preparations enriched for NK cells. Susceptibility to cytolytic granules isolated from rat LGL tumor cells remained the same after treatment of Molt-4 or K562 with PI-PLC. Combined treatment of Molt-4 with PI-PLC and rlFN-α or rlFN-γ resulted in additive reductions of the NK susceptibility, suggesting that PI-PLC and interferons act on different mechanisms to protect cells from NK lysis. When expression of a number of antigens on Molt-4 and K562 was analyzed in flow cytometry, only the expression of CD58 was reduced after PI-PLC treatment. The susceptibility of Con A blasts to MLR derived cytotoxic T-cells was not altered by treatment with phospholipase. These data suggest that PI-PLC treatment reduces the capacity of some target cells to activate NK cells upon contact. The mechanism behind this phenomenon is presently unclear.</description><subject>Antigens, CD - analysis</subject><subject>Antigens, Differentiation - analysis</subject><subject>Biological and medical sciences</subject><subject>CD58 Antigens</subject><subject>Cell Line</subject><subject>Cytoplasmic Granules - enzymology</subject><subject>Cytotoxic reactions (adcc reaction, cell-mediated lympholysis, complement-dependent cytotoxicity and others)</subject><subject>Cytotoxicity, Immunologic - drug effects</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunity, Innate - drug effects</subject><subject>Immunobiology</subject><subject>Immunological reactions in vitro</subject><subject>In Vitro Techniques</subject><subject>Interferon Type I - pharmacology</subject><subject>Interferon-gamma - pharmacology</subject><subject>Killer Cells, Natural - immunology</subject><subject>Lymphocyte Activation</subject><subject>Signal Transduction - drug effects</subject><subject>T-Lymphocytes - immunology</subject><subject>Type C Phospholipases - pharmacology</subject><issn>0008-8749</issn><issn>1090-2163</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc-O1DAMhysEWmYX3gCkHBCCQ8Fp2rS5IKHRLCBWwAHOUZo406D-GeJ00TwLL0vLjJYbnCzF38-K_WXZEw6vOHD5GgCavKlL9ULxlwp4U-W7e9mGg4K84FLczzZ3yMPskug7AOelgovsgtcgVFFtsl9fuokO3dSHgyFkW5YimjTgmNjkmcWYTBhZNw9mZMnEPablse-JRXSzRWKpwxAZzWTxkEIb-pCOLE3s00fWHykQ-xlSN82JGe_RpjDuWRtGt9ZpyeFIIYXbc6g_pmDZPppx7pEeZQ-86Qkfn-tV9u1693X7Pr_5_O7D9u1NbkUjUl5bCSB40TgvlWva0nFVgrSWl56LtnVQcm-kk8pL770xtatkuazfFAKKSoir7Plp7iFOP2akpIdA65ZmxGkm3UAphKrgvyCvFBdKyQUsT6CNE1FErw8xDCYeNQe9ytOrGb2a0YrrP_L0bok9Pc-f2wHd39DJ1tJ_du4bsqb3y51soDusklCUVb1gb04YLke7DRg12YCjRRfiokC7Kfz7H78B04G4-Q</recordid><startdate>199103</startdate><enddate>199103</enddate><creator>Une, Clas</creator><creator>Grönberg, Alvar</creator><creator>Axberg, Inger</creator><creator>Jondal, Mikael</creator><creator>Örn, Anders</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>199103</creationdate><title>Phospholipase C treatment of certain human target cells reduces their susceptibility to NK lysis without affecting binding or sensitivity to lytic granules</title><author>Une, Clas ; Grönberg, Alvar ; Axberg, Inger ; Jondal, Mikael ; Örn, Anders</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-7c6003128df69d8b4d19406cc14f13bbd041fa6d69f6fffaa7d56439282302533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Antigens, CD - analysis</topic><topic>Antigens, Differentiation - analysis</topic><topic>Biological and medical sciences</topic><topic>CD58 Antigens</topic><topic>Cell Line</topic><topic>Cytoplasmic Granules - enzymology</topic><topic>Cytotoxic reactions (adcc reaction, cell-mediated lympholysis, complement-dependent cytotoxicity and others)</topic><topic>Cytotoxicity, Immunologic - drug effects</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunity, Innate - drug effects</topic><topic>Immunobiology</topic><topic>Immunological reactions in vitro</topic><topic>In Vitro Techniques</topic><topic>Interferon Type I - pharmacology</topic><topic>Interferon-gamma - pharmacology</topic><topic>Killer Cells, Natural - immunology</topic><topic>Lymphocyte Activation</topic><topic>Signal Transduction - drug effects</topic><topic>T-Lymphocytes - immunology</topic><topic>Type C Phospholipases - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Une, Clas</creatorcontrib><creatorcontrib>Grönberg, Alvar</creatorcontrib><creatorcontrib>Axberg, Inger</creatorcontrib><creatorcontrib>Jondal, Mikael</creatorcontrib><creatorcontrib>Örn, Anders</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cellular immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Une, Clas</au><au>Grönberg, Alvar</au><au>Axberg, Inger</au><au>Jondal, Mikael</au><au>Örn, Anders</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phospholipase C treatment of certain human target cells reduces their susceptibility to NK lysis without affecting binding or sensitivity to lytic granules</atitle><jtitle>Cellular immunology</jtitle><addtitle>Cell Immunol</addtitle><date>1991-03</date><risdate>1991</risdate><volume>133</volume><issue>1</issue><spage>127</spage><epage>137</epage><pages>127-137</pages><issn>0008-8749</issn><eissn>1090-2163</eissn><coden>CLIMB8</coden><abstract>Phosphatidylinositol-specific phospholipase C (PI-PLC) is an enzyme that has the capacity to release glycosyl-phosphatidyl inositol (G-PI)-anchored proteins from the cell surface. Pretreatment of the human T-cell leukemia cell line Molt-4 with PI-PLC resulted in a decrease in the susceptibility to lysis by natural killer (NK) cells. Treatment of the erythroleukemia cell line K562 with PI-PLC had no effect on its NK susceptibility. PI-PLC-treated and untreated Molt-4 bound equally well to lymphocytes in target-binding studies with effector cell preparations enriched for NK cells. Susceptibility to cytolytic granules isolated from rat LGL tumor cells remained the same after treatment of Molt-4 or K562 with PI-PLC. Combined treatment of Molt-4 with PI-PLC and rlFN-α or rlFN-γ resulted in additive reductions of the NK susceptibility, suggesting that PI-PLC and interferons act on different mechanisms to protect cells from NK lysis. When expression of a number of antigens on Molt-4 and K562 was analyzed in flow cytometry, only the expression of CD58 was reduced after PI-PLC treatment. The susceptibility of Con A blasts to MLR derived cytotoxic T-cells was not altered by treatment with phospholipase. These data suggest that PI-PLC treatment reduces the capacity of some target cells to activate NK cells upon contact. The mechanism behind this phenomenon is presently unclear.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>1703925</pmid><doi>10.1016/0008-8749(91)90185-E</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-8749 |
| ispartof | Cellular immunology, 1991-03, Vol.133 (1), p.127-137 |
| issn | 0008-8749 1090-2163 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80433950 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antigens, CD - analysis Antigens, Differentiation - analysis Biological and medical sciences CD58 Antigens Cell Line Cytoplasmic Granules - enzymology Cytotoxic reactions (adcc reaction, cell-mediated lympholysis, complement-dependent cytotoxicity and others) Cytotoxicity, Immunologic - drug effects Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunity, Innate - drug effects Immunobiology Immunological reactions in vitro In Vitro Techniques Interferon Type I - pharmacology Interferon-gamma - pharmacology Killer Cells, Natural - immunology Lymphocyte Activation Signal Transduction - drug effects T-Lymphocytes - immunology Type C Phospholipases - pharmacology |
| title | Phospholipase C treatment of certain human target cells reduces their susceptibility to NK lysis without affecting binding or sensitivity to lytic granules |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T05%3A31%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phospholipase%20C%20treatment%20of%20certain%20human%20target%20cells%20reduces%20their%20susceptibility%20to%20NK%20lysis%20without%20affecting%20binding%20or%20sensitivity%20to%20lytic%20granules&rft.jtitle=Cellular%20immunology&rft.au=Une,%20Clas&rft.date=1991-03&rft.volume=133&rft.issue=1&rft.spage=127&rft.epage=137&rft.pages=127-137&rft.issn=0008-8749&rft.eissn=1090-2163&rft.coden=CLIMB8&rft_id=info:doi/10.1016/0008-8749(91)90185-E&rft_dat=%3Cproquest_cross%3E80433950%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15913996&rft_id=info:pmid/1703925&rft_els_id=000887499190185E&rfr_iscdi=true |